Natural and synthetic derivatives of vitamin A (retinoids), are active in cancer therapy and chemoprevention. Mechanisms involved in these clinical effects and why retinoid resistance occurs need to be better understood. This is the objective of this revised NIH R01-CA87546 competing renewal application that examines comprehensively, use of classical and non-classical retinoids as tools to uncover chemopreventive mechanisms. Work from the prior finding cycle revealed that all- trans-retinoic acid (RA) prevented tobacco-carcinogenic transformation of human bronchial epithelial (HBE) cells through novel mechanisms. These involved proteasomal degradation of cyclin D1 and transcriptional repression of the epidermal growth factor receptor (EGFR) that each repressed cyclin D1. The resulting G1 arrest permitted repair of carcinogenic damage to DNA and thereby conferred chemoprevention. Cyclin D1 was a molecular target for both pathways. Notably, these pathways were each deregulated in RA-resistant HBE cells that we derived and found to exhibit retinoic acid receptor-beta (RARbeta) silencing, as often occurs in lung carcinogenesis. A novel RARbeta isoform was also discovered that could account for clinical retinoid resistance. Notably, retinoid X receptor (RXR) agonists (rexinoids) by-passed this RARbeta3 block and activated similar down-stream pathways as classical retinoids to repress cyclin D1.
The specific aims will: (1) comprehensively explore using cultured HBE and lung cancer cells that are sensitive or resistant to all-trans-retinoic acid (RA) whether transcriptional or post-transcriptional chemopreventive mechanisms engaged by classical or non-classical retinoids confer D-type cyclin repression. Function of the novel RARbeta isoform will be studied. Whether cooperation with demethylation agents restores RARbeta expression and retinoid response and whether repressing D-type cyclins by siRNA targeting or EGFR inhibition enhances retinoid or rexinoid response will be learned. (2) Studies that target for chemoprevention D-type cyclins in carcinogen-induced and transgenic mouse models will be conducted. (3) Findings will be translated to the clinic using unique tissues harvested from proof of principle trials that target D-type cyclins. These trials are yielding exciting preliminary findings that validate D-type cyclins as chemopreventive targets. Unique pre-clinical and clinical models and resources are available. Successful achievement of these aims will improve understanding how classical or non-classical retinoids exert chemopreventive effects. These findings would translate this work from the bench to the bedside to advance a mechanism-based approach to cancer chemoprevention. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA087546-06A1
Application #
7047611
Study Section
Special Emphasis Panel (ZRG1-CDP (01))
Program Officer
Crowell, James A
Project Start
2000-07-01
Project End
2011-04-30
Budget Start
2006-05-09
Budget End
2007-04-30
Support Year
6
Fiscal Year
2006
Total Cost
$282,064
Indirect Cost
Name
Dartmouth College
Department
Pharmacology
Type
Schools of Medicine
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Mustachio, Lisa Maria; Lu, Yun; Kawakami, Masanori et al. (2018) Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target. Cancer Res 78:587-592
Chen, Limo; Diao, Lixia; Yang, Yongbin et al. (2018) CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov 8:1156-1175
Kawakami, Masanori; Mustachio, Lisa Maria; Liu, Xi et al. (2018) Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers. Mol Cancer Ther 17:724-731
Kawakami, Masanori; Mustachio, Lisa Maria; Zheng, Lin et al. (2018) Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. Proc Natl Acad Sci U S A 115:1913-1918
Sepesi, Boris; Gold, Kathryn A; Correa, Arlene M et al. (2017) The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer. J Thorac Oncol 12:1280-1287
Kawakami, Masanori; Mustachio, Lisa Maria; Rodriguez-Canales, Jaime et al. (2017) Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. J Natl Cancer Inst 109:
Mustachio, Lisa Maria; Lu, Yun; Tafe, Laura J et al. (2017) Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer. Mol Cancer Res 15:905-914
Mustachio, Lisa Maria; Kawakami, Masanori; Lu, Yun et al. (2017) The ISG15-specific protease USP18 regulates stability of PTEN. Oncotarget 8:3-14
Yim, Christina Y; Sekula, David J; Hever-Jardine, Mary P et al. (2016) G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program. Cancer Res 76:1204-13
Danilov, Alexey V; Hu, Shanhu; Orr, Bernardo et al. (2016) Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2. Mol Cancer Ther 15:2758-2766

Showing the most recent 10 out of 74 publications